Skip to content

Study · Randomized controlled trial · n = 273 · 2000

9 results

Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group.

Albano C, Felberbaum RE, Smitz J, Riethmüller-Winzen H, Engel J, Diedrich K, Devroey P

Human reproduction (Oxford, England)1 Mar 2000Cited by 213 (Europe PMC)

PMID10686191 (opens in a new tab)DOI10.1093/humrep/15.3.526 (opens in a new tab)PepBankPUB-10686191
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In IVF/ICSI patients, 96.3% receiving cetrorelix reached HCG injection day versus 90.6% receiving buserelin.

    In plain wordsIn IVF/ICSI patients, 96.3% receiving cetrorelix reached HCG injection day versus 90.6% receiving buserelin.

    Peptide
    Cetrorelix
    Outcome
    IncreaseReaching HCG injection day
    Study

    n = 273

    Comparator
    Buserelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Reached HCG day
    181 patients
    cetrorelix
    Reached HCG day
    96.3%
    cetrorelix
    Reached HCG day
    77 patients
    buserelin
    Reached HCG day
    90.6%
    buserelin

    Source sentences

    Summary
    Ultimately, 181 patients (96.3%) in the cetrorelix group, and 77 (90.6%) in the buserelin group, reached the day of the human chorionic gonadotrophin (HCG) injection.
    1 context sentence
    Summary · context
    In this prospective and randomized study, 188 patients received the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix, and 85 patients the LHRH agonist buserelin to prevent endogenous luteinizing hormone (LH) surges during ovarian stimulation in in-vitro fertilization (IVF)/intracyt…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In IVF/ICSI patients, cetrorelix required significantly fewer HMG ampoules than buserelin (P < 0.01).

    In plain wordsIn IVF/ICSI patients, cetrorelix required significantly fewer HMG ampoules than buserelin.

    Peptide
    Cetrorelix
    Outcome
    DecreaseHMG ampoules administered
    Study

    n: not reported in source

    Comparator
    Buserelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    P value, cetrorelix vs buserelin
    < 0.01 P
    HMG ampoules, cetrorelix vs buserelin

    Source sentences

    Summary
    The mean number of human menopausal gonadotrophin (HMG) ampoules administered and the mean number of stimulation days with HMG were significantly less in the cetrorelix group than in the buserelin group (P < 0.01).
    1 context sentence
    Summary · context
    In this prospective and randomized study, 188 patients received the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix, and 85 patients the LHRH agonist buserelin to prevent endogenous luteinizing hormone (LH) surges during ovarian stimulation in in-vitro fertilization (IVF)/intracyt…
  3. 03HumanRandomized controlled trialEfficacy outcome

    In IVF/ICSI patients, cetrorelix required significantly fewer HMG stimulation days than buserelin (P < 0.01).

    In plain wordsIn IVF/ICSI patients, cetrorelix required significantly fewer HMG stimulation days than buserelin.

    Peptide
    Cetrorelix
    Outcome
    DecreaseHMG stimulation days
    Study

    n: not reported in source

    Comparator
    Buserelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    P value, cetrorelix vs buserelin
    < 0.01 P
    HMG stimulation days, cetrorelix vs buserelin

    Source sentences

    Summary
    The mean number of human menopausal gonadotrophin (HMG) ampoules administered and the mean number of stimulation days with HMG were significantly less in the cetrorelix group than in the buserelin group (P < 0.01).
    1 context sentence
    Summary · context
    In this prospective and randomized study, 188 patients received the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix, and 85 patients the LHRH agonist buserelin to prevent endogenous luteinizing hormone (LH) surges during ovarian stimulation in in-vitro fertilization (IVF)/intracyt…
  4. 04HumanRandomized controlled trialEfficacy outcome

    In IVF/ICSI patients, cetrorelix produced fewer 11-14 mm follicles on HCG day than buserelin.

    In plain wordsIn IVF/ICSI patients, fewer small follicles were present on HCG day with cetrorelix than with buserelin.

    Peptide
    Cetrorelix
    Outcome
    DecreaseSmall follicles on HCG day
    Study

    n: not reported in source

    Comparator
    Buserelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    On the day of the HCG administration, more follicles of a small diameter (11-14 mm) were observed in the buserelin group than in the cetrorelix group (P = 0. 02) and the mean serum oestradiol concentration was significantly higher in patients who received buserelin than in those who received cetrorelix (P < 0.01).
    1 context sentence
    Summary · context
    In this prospective and randomized study, 188 patients received the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix, and 85 patients the LHRH agonist buserelin to prevent endogenous luteinizing hormone (LH) surges during ovarian stimulation in in-vitro fertilization (IVF)/intracyt…
  5. 05HumanRandomized controlled trialEfficacy outcome

    In IVF/ICSI patients, serum oestradiol on HCG day was significantly lower with cetrorelix than with buserelin (P < 0.01).

    In plain wordsIn IVF/ICSI patients, serum oestradiol on HCG day was significantly lower with cetrorelix than with buserelin.

    Peptide
    Cetrorelix
    Outcome
    DecreaseSerum oestradiol on HCG day
    Study

    n: not reported in source

    Comparator
    Buserelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    P value, cetrorelix vs buserelin
    < 0.01 P
    serum oestradiol on HCG day, cetrorelix vs buserelin

    Source sentences

    Summary
    and the mean serum oestradiol concentration was significantly higher in patients who received buserelin than in those who received cetrorelix (P < 0.01).
    1 context sentence
    Summary · context
    In this prospective and randomized study, 188 patients received the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix, and 85 patients the LHRH agonist buserelin to prevent endogenous luteinizing hormone (LH) surges during ovarian stimulation in in-vitro fertilization (IVF)/intracyt…
  6. 06HumanRandomized controlled trialEfficacy outcome

    In IVF/ICSI patients, fertilization rates were similar between cetrorelix and buserelin.

    In plain wordsIn IVF/ICSI patients, fertilization rates were similar between cetrorelix and buserelin.

    Peptide
    Cetrorelix
    Outcome
    Direction not reportedFertilization rate
    Study

    n: not reported in source

    Comparator
    Buserelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similar results were observed in fertilization, cleavage and pregnancy rates in the two groups.
    1 context sentence
    Summary · context
    In this prospective and randomized study, 188 patients received the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix, and 85 patients the LHRH agonist buserelin to prevent endogenous luteinizing hormone (LH) surges during ovarian stimulation in in-vitro fertilization (IVF)/intracyt…
  7. 07HumanRandomized controlled trialEfficacy outcome

    In IVF/ICSI patients, cleavage rates were similar between cetrorelix and buserelin.

    In plain wordsIn IVF/ICSI patients, cleavage rates were similar between cetrorelix and buserelin.

    Peptide
    Cetrorelix
    Outcome
    Direction not reportedCleavage rate
    Study

    n: not reported in source

    Comparator
    Buserelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similar results were observed in fertilization, cleavage and pregnancy rates in the two groups.
    1 context sentence
    Summary · context
    In this prospective and randomized study, 188 patients received the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix, and 85 patients the LHRH agonist buserelin to prevent endogenous luteinizing hormone (LH) surges during ovarian stimulation in in-vitro fertilization (IVF)/intracyt…
  8. 08HumanRandomized controlled trialEfficacy outcome

    In IVF/ICSI patients, pregnancy rates were similar between cetrorelix and buserelin.

    In plain wordsIn IVF/ICSI patients, pregnancy rates were similar between cetrorelix and buserelin.

    Peptide
    Cetrorelix
    Outcome
    Direction not reportedPregnancy rate
    Study

    n: not reported in source

    Comparator
    Buserelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similar results were observed in fertilization, cleavage and pregnancy rates in the two groups.
    1 context sentence
    Summary · context
    In this prospective and randomized study, 188 patients received the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix, and 85 patients the LHRH agonist buserelin to prevent endogenous luteinizing hormone (LH) surges during ovarian stimulation in in-vitro fertilization (IVF)/intracyt…
  9. 09HumanNon-randomized trialEfficacy outcome

    In IVF/ICSI patients receiving cetrorelix, three of 188 patients (1.6%) showed a rise in LH and progesterone.

    In plain wordsIn IVF/ICSI patients receiving cetrorelix, three of 188 patients (1.6%) showed a rise in LH and progesterone.

    Peptide
    Cetrorelix
    Outcome
    Not applicableLH and progesterone rise
    Study

    n = 188

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Patients with LH and progesterone rise
    3 patients
    cetrorelix group (n=188)
    LH and progesterone rise incidence
    1.6%
    cetrorelix group (n=188)

    Source sentences

    Summary
    A rise in LH and progesterone concentrations was observed in three of the 188 patients (1.6%) who received cetrorelix.
    1 context sentence
    Summary · context
    In this prospective and randomized study, 188 patients received the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix, and 85 patients the LHRH agonist buserelin to prevent endogenous luteinizing hormone (LH) surges during ovarian stimulation in in-vitro fertilization (IVF)/intracyt…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.